RB1 and retinoblastoma: Certainly there is evidence for the cost-effectiveness of specific exemplars, for example RB1 mutation testing in retinoblastoma-affected families (S80–S81) (Fig. 2); and use of genomic technologies in implementation of preventative strategies in specific areas, such as populations with high levels of consanguinity and a significant burden of autosomal recessive disease (S82).